Suprefact is generally used to provide therapeutic benefit in clinical contexts that involve acute or unstable symptom patterns, which is relevant in conditions characterized by periods of heightened symptoms associated with hormonal imbalance. Its use is focused on conditions where functional stability becomes affected and is applied across domains where additional symptomatic support is needed.

Therapeutic Benefit and Core Uses

This medication is commonly applied in the context of conditions associated with acute or disruptive episodes, such as advanced prostate carcinoma and certain forms of premenopausal breast cancer. It is also relevant for conditions presenting with significant symptomatic burden, including endometriosis and uterine fibroids, and is used in protocols for in-vitro fertilization (IVF). In clinical use, it is considered relevant for the treatment of endometriosis in patients who do not require surgery as primary therapy.

It is applied to ease challenging symptoms, including severe chronic pelvic pain, dysmenorrhea (painful periods), and excessive uterine bleeding. The resulting symptomatic relief helps patients cope more steadily with difficult episodes and contributes to easing the overall symptom load.

---

Quick Fact: Relief for Hormone-Driven Discomfort

Context	Symptom Management Area	Benefit
Oncology	Symptoms linked to organ-specific functional stress	Helps manage disease progression
Gynecology	Symptoms related to physical discomfort	Contributes to easing the symptom load
Fertility	Symptoms associated with acute or episodic changes	Supports functional stability

Regulatory References

1. Health Canada Product Monograph

Eligibility Map: Who Can and Cannot Use Suprefact (Buserelin) — Official Regulatory Information

This information reflects eligibility and exclusion criteria strictly defined in government regulatory documents.

Populations for whom use is Contraindicated (Must Not Use):

• Patients with known hypersensitivity to buserelin, other LHRH/GnRH agonists, or any component of the formulation.
• Women who are pregnant or breastfeeding.
• Females presenting with undiagnosed abnormal vaginal bleeding.
• Male patients with prostate cancer who have undergone orchiectomy or whose tumour is non-hormone-dependent.
• Infants and newborns (specifically for injection formulations containing Benzyl Alcohol).
• Patients with congenital Long QT syndrome (for depot formulations).

---

Populations Requiring Special Caution (Conditional Use):

• Patients with diabetes must have blood glucose checked regularly due to the risk of worsening metabolic control.
• Patients with risk factors for osteoporosis require particular caution, as treatment may lead to loss of bone mineral content.
• Caution is advised for patients with existing cardiovascular risk factors (e.g., hypertension, heart disease, Long QT risk).
• The effect of buserelin may be prolonged in patients with severe hepatic or renal function disturbances.

---

Age and Duration Rules:

• Pediatric patients (<18 years) are generally not established for endometriosis treatment.
• Treatment for benign gynecological conditions is limited in duration (e.g., maximum of six months).

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Buserelin acetate (Suprefact) primarily through pharmacodynamic interactions, which relate to the additive effects of substances rather than metabolic or pharmacokinetic interference. There are no formal drug-drug contraindications listed in regulatory labeling based on interaction risk.

---

Documented Pharmacodynamic Interactions

The most relevant documented interactions concern two specific medicine categories:

• Medicinal Products that Prolong the QTc Interval: Co-administration with drugs known to prolong the QTc interval, such as specific Class IA antiarrhythmics (e.g., quinidine, disopyramide) and Class III antiarrhythmics (e.g., amiodarone, sotalol, dofetilide), carries an increased risk or severity of QTc prolongation. This cautionary statement is tied to the hormonal effects of androgen deprivation therapy.

• Antidiabetic Agents: Concomitant use with agents such as insulin or oral hypoglycemics may lead to an attenuation of the antidiabetic effect, potentially worsening the patient’s metabolic control. Regular checking of blood glucose levels is necessary when these agents are co-administered.

Restrictions and Considerations

The official labeling notes that caution is required when prescribing Buserelin alongside QTc-prolonging medicines in patients with pre-existing cardiac risk factors (e.g., congenital long QT syndrome, relevant electrolyte imbalances, or congestive heart failure). No specific timing rules requiring the separation of doses by a set number of hours are documented. Additionally, there are no explicitly documented interactions with food, alcohol, or herbal products.

How Suprefact Works: Mechanism of Action

Suprefact (Buserelin acetate) is a synthetic Gonadotropin-Releasing Hormone ( GnRH) agonist that operates by modulating the central Hypothalamic-Pituitary-Gonadal (HPG) axis. Its mechanism is biphasic, involving a crucial transition from initial stimulation to sustained suppression.

Biphasic Modulation of Pituitary GnRH Receptors

The drug's action begins at the GnRH Receptors ( GnRH-R) on the pituitary gland's gonadotroph cells. Buserelin initially acts as an agonist, causing a transient release of Luteinizing Hormone ( LH) and Follicle-Stimulating Hormone ( FSH) (the "flare effect"). The continuous, non-pulsatile presence of Buserelin then triggers the crucial second step: the down-regulation and desensitization of the GnRH-R system. This results in a functional shutdown of the pituitary's ability to secrete LH and FSH.

Sustained Suppression of Gonadal Steroidogenesis

The lack of LH and FSH signal flowing from the pituitary gland to the gonads leads to the core physiological consequence. Since the gonads require these trophic hormones to produce sex hormones, the sustained inhibition causes a reduction in circulating Testosterone and Estradiol levels. This sustained inhibition of gonadal steroidogenesis achieves a hypogonadal physiological state, which is the final output of the drug's mechanism of action. The full suppressive effect requires several weeks for the receptor down-regulation process to complete.

Official Administration Guidelines for Suprefact (Buserelin)

Administration of Buserelin (Suprefact) is guided by the specific formulation used and the treatment phase.

Formulation	Route of Administration	Standard Adult Dosing Schedule
Solution for Injection (1 mg/ mL)	Subcutaneous (SC)	Initial Phase (Oncology): 500 mu g SC, three times daily (TID) for 7 days. IVF: 200 mu g to 500 mu g SC, once daily.
Nasal Spray	Intranasal (IN)	Maintenance Phase/Endometriosis: 400 mu g into each nostril, three times daily.
Subcutaneous Implant (Depot)	Subcutaneous (SC)	6.3 mg implant every two calendar months or 9.45 mg implant every three calendar months.

---

Procedural and Timing Requirements

Individual doses, regardless of the route, must be administered at approximately equal intervals; adherence to this schedule is critical for maintaining consistent suppression levels. The initiation of SC injection therapy is often most conveniently carried out under hospital supervision.

Special Conditions: For prostate carcinoma treatment, the administration of an anti-androgen is required to begin approximately 5 days before the first Buserelin dose and must continue for the initial 3 to 4 weeks. For patients using the nasal spray, nasal passages should be cleared prior to use, and any other nasal products must be deferred for at least 30 minutes. The 9.45 mg Depot implant is not indicated for use in children.

Suprefact: Recent Clinical Evidence

Chronic Pain Management

Studies have investigated the use of Suprefact in chronic pain. Research evaluated whether Suprefact use was associated with changes in patient-reported severity.

• One long-term observational study in 400 participants with chronic musculoskeletal pain examined the relationship between consistent use of Suprefact and pain outcomes over a 12-month period.
• Another double-blind, placebo-controlled trial in 150 patients explored the magnitude of the measured outcome on pain scores using the Visual Analogue Scale (VAS).

Neuropathic Symptom Studies

Studies have evaluated the use of Suprefact for participants with a range of neuropathic symptoms.

• A Phase II trial in 120 participants with diabetic neuropathy investigated whether Suprefact use was associated with differences in symptoms like burning, tingling, and numbness.
• Other laboratory-based research and early-stage human trials have explored the role of Suprefact in relation to nerve excitability and function.

Research has investigated whether the use of Suprefact was associated with changes in the frequency of pain episodes.

Combination Therapy and Dosing

Research has compared the outcomes of combination therapy using Suprefact and Therapy X with monotherapy.

• A study in patients with refractory pain examined whether the addition of Suprefact to an existing regimen of Therapy X was associated with differences in reported pain severity or quality of life when compared to continuing Therapy X alone.
• The results of this study indicated mixed findings regarding the incremental effect of adding Suprefact.

Some studies explored different starting dosages for participants with moderate symptoms.

• A dose-ranging study evaluated three different daily dosages of Suprefact (low, medium, and high) to investigate different doses and reported outcomes on pain scores over a four-week period.

Key Studies & References Phase II Investigation of Suprefact for Symptomatic Diabetic Neuropathy

Common questions about Suprefact (FAQ)

---

Q: Are the side effects of Suprefact usually temporary?

A: Many of the common side effects, such as hot flashes and fatigue, are an expected result of the medicine's primary purpose: creating a state of controlled hormonal suppression. Official product information describes this hormonal suppression as reversible once treatment has been fully stopped. In line with this, the side effects resulting from the intended hormonal changes typically begin to subside after the treatment period has concluded.

Q: How quickly can someone expect Suprefact to start working?

A: Regulatory sources describe the medicine's action beginning with an initial, temporary increase in hormones known as a 'flare effect.' This is followed by the intended hormonal suppression. Official information indicates that hormone levels typically reach the desired low (the therapeutic range) within two to four weeks after the treatment is started.

Q: Can Suprefact cause hot flashes, and how long do they typically last?

A: Hot flashes (flushing) are a common and expected side effect, as they are caused by the controlled decrease in sex hormones that the medicine is designed to achieve. While the intensity may change, official product information suggests that these hormonal side effects generally persist throughout the period that the medication is being administered.

Q: Does Suprefact cause headaches, and are they severe?

A: Headache is listed in regulatory documents as a common adverse reaction associated with the use of Suprefact. Regulatory sources classify common reactions as those affecting fewer than 1 in 10 patients, but they do not provide a specific classification of the headache severity (such as mild or severe) in the prescribing information.

Q: What kind of monitoring or tests are typically required while using Suprefact?

A: The official product labeling recommends that patients receive regular clinical assessment and appropriate laboratory tests while using the medicine. For specific uses, such as prostate carcinoma, this monitoring may include determining Prostate Specific Antigen (PSA) and testosterone levels in the serum.

Q: What should I know about Suprefact before a surgery?

A: For prostate carcinoma treatment, regulatory documents note that an anti-androgen medicine is to be started approximately five days before the first Suprefact dose. This is meant to manage the initial hormonal flare effect and must continue for the initial three to four weeks of treatment.

Q: Are there specific instructions for traveling with Suprefact?

A: Official storage instructions are essential for maintaining the medicine's effectiveness. Suprefact must not be stored above 25 °C and it is explicitly stated that the product must not be frozen. The medication should also be protected from light.

Q: Can Suprefact be used by people with kidney problems?

A: Official warnings advise that caution is needed for patients with severe renal (kidney) function disturbances. This caution is given because the effects of the active substance, buserelin, may be prolonged in these individuals.

Q: Is it normal to feel more tired than usual when taking Suprefact?

A: Fatigue is listed in regulatory documents as a common side effect. Since a common side effect is an expected occurrence, the experience of feeling tired is consistent with the medicine's safety profile.

Q: What happens if a scheduled Suprefact administration is slightly delayed?

A: Regulatory documents state that all doses, regardless of the medicine's form, must be administered at approximately equal intervals. For the long-acting Depot implant, a considerable extension of the dosing interval may lead to a brief recovery of testosterone secretion, which counteracts the medicine's intended effect.

Q: What does the official research say about the long-term use of Suprefact?

A: Official documents highlight potential long-term safety considerations related to the medically induced low-hormone state. These include a possible decrease in bone mineral density over time and an increased risk of serious cardiovascular events in men receiving treatment for prostate cancer.

Q: Does Suprefact affect fertility in men or women?

A: Official guidance indicates that Buserelin can cause sterility in men and is expected to induce a state similar to menopause in women.

Q: Is there a maximum amount of time someone can be on Suprefact therapy?

A: For benign gynecological conditions, the treatment duration is often limited (e.g., maximum of six months). For chronic conditions like advanced carcinoma, treatment is generally long-term, and the appropriate duration is determined based on the individual's clinical needs.

Q: Are the effects of Suprefact reversible after treatment stops?

A: The overall mechanism of the drug is intended to induce a state of controlled, reversible hormonal suppression. The effects of the medicine are expected to reverse after the course of treatment is complete.

Q: Is Suprefact known to interact with alcohol consumption?

A: Official product information suggests that the drinking of alcohol, in small amounts, does not appear to affect the safety or usefulness of the medicine itself. However, chronic abuse of alcohol is cited in regulatory documents as a risk factor for decreased bone mineral content during treatment.

Q: Do people need to avoid certain foods or drinks while using Suprefact?

A: There are no explicitly documented interactions with food mentioned in the official prescribing information. Guidance for the nasal spray formulation notes that it can be used before or after meals to aid in following the dose schedule.

Q: Does Suprefact have a weight gain side effect?

A: Yes, weight gain is listed as an adverse reaction in official regulatory documents.

Q: Does age affect who can or cannot use Suprefact?

A: The long-acting Depot implant formulation is not indicated for use in children. Official documents state that pediatric use for other conditions is generally not established.

Q: Can Suprefact impact bone density over time?

A: The resulting low-hormone state caused by the medicine can lead to decreased bone mineral density (BMD) and a possible increased risk of fracture. For this reason, caution is advised for patients who already have risk factors for osteoporosis.

Q: Is Suprefact used for children or adolescents in any specific conditions?

A: While use is not established for conditions like endometriosis in this age group, other medicines in the same classification (GnRH agonists) are used in some regions for conditions such as Central Precocious Puberty (CPP).

Q: How long does Suprefact stay in the body after the last dose?

A: The injectable form has a relatively short elimination half-life, which is the time it takes for half of the dose to leave the body, approximately 72 to 80 minutes. However, the continuous-release Depot implant's effect and the resulting hormonal suppression last for a much longer, specified period.

Q: Does Suprefact affect cholesterol levels?

A: Yes, official safety information indicates that the medicine is associated with adverse effects on cardiovascular risk factors, including changes in serum lipoproteins and hypercholesterolemia (elevated cholesterol levels).

Q: Is Suprefact a controlled substance?

A: Suprefact is classified as a prescription-only medicine. This means that, in all jurisdictions, it legally requires authorization from a licensed healthcare provider to be dispensed.

Q: Does Suprefact cause changes in vision?

A: Yes, regulatory safety documents list impaired vision and other ophthalmic disorders (such as dryness or irritation) as reported adverse events associated with the medicine's use.

Q: Are there different strengths of Suprefact available?

A: Different strengths are available across the various forms of the medicine. These include the 1 mg/mL solution for injection, and the long-acting Depot implants in strengths of 6.3 mg and 9.45 mg.

Q: What is the primary difference between Suprefact and a GnRH antagonist?

A: Suprefact is a GnRH agonist, which initially stimulates the pituitary gland before achieving long-term hormonal suppression. In contrast, a GnRH antagonist achieves suppression immediately by directly and competitively blocking the GnRH receptor from the start.

Suprefact must be stored according to specific regulatory requirements to maintain its stability. The medication must not be stored above 25 °C and it is essential that the product not be frozen. The injection vials must be kept in the original outer carton to ensure protection from light.

Stability and Use-By Limits

The stability of the product changes upon opening. Once the multidose injection vial is opened, the contents must be used within 15 days. The nasal spray formulation must be discarded after one week following the first use.

Disposal and Safety

For child safety, the medicine must be stored out of the sight and reach of children. Any unused or expired product must be disposed of in accordance with local requirements and should not be thrown away via household waste or wastewater.